查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837459

鬱血性心臟衰竭設備市場（按設備類型、治療方式、最終用戶和分銷管道）—全球預測 2025-2032

Congestive Heart Failure Treatment Device Market by Device Type, Therapeutic Modality, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

鬱血性心臟衰竭設備市場預計到 2032 年將成長至 256.4 億美元，複合年成長率為 8.40%。

主要市場統計數據
基準年2024年 134.4億美元
預計2025年 146億美元
預測年份：2032年 256.4億美元
複合年成長率（%） 8.40%

重塑鬱血性心臟衰竭選擇和治療途徑的臨床、技術和商業性促進因素的簡明框架

鬱血性心臟衰竭衰竭仍然是最重要的慢性心血管疾病之一，對臨床系統、護理路徑和設備創新者造成壓力。過去十年，治療模式已從症狀治療發展為以電調節和機械循環支持為目標的設備為基礎的干涉措施。這種轉變反映了植入式技術、手術全期護理和長期監測方面的進步，並對設備耐用性、患者生活品質和後續護理經濟性提出了新的期望。

隨著臨床團隊擴大將遠端監控和循證選擇標準融入其中，製造商和醫療保健提供者必須將產品設計與實際可用性和長期療效相結合。同時，嚴格的監管和付款方審查要求可靠的臨床證據和可證明的成本效益。因此，相關人員必須在臨床創新與實際考慮（例如供應鏈彈性、分銷模式和最終用戶培訓）之間取得平衡。本引言將重點放在臨床、技術和商業性促進因素之間的相互關聯，這些因素推動設備製造商、醫院系統和專科診所的短期策略選擇。

技術小型化、數位連接和基於價值的護理模式將如何改變設備開發和臨床應用格局

隨著電刺激、機械循環支援和數位健康等領域的創新融合，鬱血性心臟衰竭領域正在迅速變化，從而催生新的護理標準。設備小型化、電池技術和基於軟體的治療控制方面的進步，擴大了植入式心臟整流去顫器和心臟再同步治療設備的臨床適應症和可用性。同時，材料的改進、經皮路和增強的血流動力學控制演算法正在降低圍手術全期風險，並擴大耐用輔助人工心臟的適用範圍。

同時，醫療系統正在採用基於價值的採購和與結果掛鉤的合約模式，迫使製造商優先考慮長期生存數據、降低再入院率和整合服務模式。數位化連接正在將遠端患者監護引入設備治療，使其成為設備治療的重要輔助手段，從而實現及時干預並減輕急診機構的負擔。因此，市場參與企業正在從產品交易銷售轉向全面的服務組合、捆綁式醫療服務和協調一致的護理路徑。這種轉型需要臨床、競爭和監管策略的緊密協調，以保持競爭力並實現患者治療結果的顯著改善。

美國關稅和貿易政策動態對採購、製造本地化和臨床供應連續性的定性累積影響

美國近期的關稅變化正在對心臟衰竭鬱血性治療設備生態系統產生累積影響，影響籌資策略、製造佈局和商業性利潤。進口關稅的上升和貿易政策的不確定性促使許多製造商重新評估其全球供應鏈，加速供應商多元化，並探索區域製造中心，以降低跨境成本波動帶來的風險。這些調整是在對易受地緣政治供應限制影響的先進設備組件（例如專用半導體、植入式電池和專有感測器）需求成長的背景下進行的。

因此，採購團隊和製造商已投資於雙重採購、合格的二級供應商以及增強的庫存管理，以降低前置作業時間風險。同時，依賴耗材的服務模式也進行了重新調整，以應對更高的到岸成本和潛在的組件供應延遲。監管備案和品管系統也需要更新，以反映新的採購制度，並維持臨床試驗和上市後監管的連續性。這些累積效應有利於那些能夠快速調整籌資策略、維持透明的供應商關係、在履行臨床支援和保固義務的同時，轉嫁或吸收成本波動的組織。

設備類型、治療方式、最終用戶設定和分銷管道如何相互作用，以影響鬱血性心臟衰竭的採用促進因素和商業策略

細分洞察揭示了不同設備類型、治療方式、最終用戶和分銷管道中不同的需求促進因素和採用模式。就設備類型而言，心臟再同步治療設備和植入式心臟整流去顫器越來越注重演算法同步和心律不整預防。在輔助人工心臟中，左心室補助人工心臟已成為晚期左心室衰竭患者持續支持的主要手段，而雙心室輔助人工心臟和右心室輔助人工心臟對於複雜的血流動力學病例仍然很重要，這些病例通常需要多學科治療團隊的協作。

另一方面，機械循環支持裝置可為晚期或難治性衰竭患者提供直接的血流動力學恢復。最終使用者表現出明顯的差異化：醫院管理全方位的急性植入和複雜的圍手術全期護理；門診手術中心促進選擇性裝置植入和低風險手術的隨訪；專科診所提供裝置管理、最佳化和長期監測，促進依從性和併發症的早期發現。直銷促進與大型醫院系統的密切合作和綜合服務協議；分銷商促進滲透到區域醫院網路和專科診所；線上銷售平台為標準化耗材、配件和遠端服務訂閱創造了機會。總而言之，這些細分揭示了有針對性的產品開發、量身定做的臨床培訓計劃以及將臨床複雜性與適當的分銷和服務投資相匹配的自適應上市模式。

區域臨床、監管和商業動態將影響美洲、歐洲、中東和非洲以及亞太市場的採用模式和戰略重點

區域動態持續影響美洲、歐洲、中東和非洲以及亞太地區的臨床應用模式、監管流程和商業策略。在美洲，整合的醫療保健體系和先進的報銷結構通常支持循證器械療法和捆綁式醫療模式的快速應用。同時，公立和私立支付機構之間的區域差異影響著採購週期和價格談判。在歐洲、中東和非洲，監管協調工作與多元化的報銷環境並存，迫使製造商制定針對特定地區的臨床證據策略，並選擇與國家衛生技術評估重點相符的市場進入順序。

在亞太地區，疾病盛行率上升、專科醫生能力提升以及中階壯大等因素共同推動了需求成長，但製造商必須調整設備設計和定價策略，以應對基礎設施、醫院容量和當地監管流程方面的差異。在各個地區，對供應鏈在地化、臨床培訓夥伴關係和遠端監控基礎設施的投資正成為成功滲透市場的關鍵要素。透過根據區域差異，策略性地調整對臨床證據產生、報銷模式和分銷的投資，企業可以最大限度地提高採用率，同時降低監管和營運風險。

區分市場領導的策略重點，例如證據產生、平台模組化和服務導向的市場競爭模式，提供了競爭優勢

活躍於鬱血性心臟衰竭領域的公司正優先考慮臨床證據生成、平台模組化和服務導向的商業模式，以在競爭格局中脫穎而出。領先的公司正在投資縱向結果研究和註冊整合，以證明再入院率的降低和功能狀態的改善。同時，產品藍圖專注於互通性、軟體主導的治療最佳化以及延長設備生命週期的升級，並透過服務協議和遠端監控訂閱創造持續的商機。

與醫院和專科診所建立策略夥伴關係正被用於加速真實世界資料收集，並共同開發臨床路徑以簡化實施。此外，為了降低地緣政治風險和關稅波動的影響，許多公司正在進行有針對性的製造業投資，包括本地生產和加強品質系統。授權合約和共同開發契約也使大公司能夠在不削弱核心競爭力的情況下擴大產品組合。整體而言，那些能夠平衡嚴謹的臨床證據項目、靈活應變的商業性可行性和富有韌性的營運模式的公司，最有可能獲得長期的臨床和經濟價值。

為醫療設備製造商和供應商合作夥伴提供策略手冊，以確保採用、管理關稅風險並實現永續的商業性成果

產業領導者應採取一系列協同行動，在技術和政策逆境中維護臨床可信度、加速應用並保護淨利率。首先，優先在不同的病人群體和真實世界環境中產生強力的臨床證據，以支持報銷討論並證明其相對有效性。其次，實現零件採購多元化，確保替代供應商，同時投資本地製造和組裝能力，以降低關稅和物流風險。第三，設計模組化設備平台和軟體升級路徑，以實現漸進式創新，降低產品過時風險，並持續透過服務收益。

此外，我們與醫院、專科診所和門診手術中心建立深度臨床夥伴關係關係，共同開發精簡的護理路徑和有針對性的培訓，以減少移植併發症並最佳化追蹤。我們整合遠端監控和患者參與工具，以保持護理的連續性，並提供數據支援基於價值的合約。最後，我們針對監管和資費變化進行情境規劃，根據付款人的預期調整定價策略，並為直銷、經銷商合作和數位管道製定清晰的商業性方案，以確保市場覆蓋率和永續成長。

策略建議以透明且穩健的混合方法研究途徑為基礎，該方法結合了相關人員的參與、臨床證據審查和供應鏈分析

本分析所依據的調查方法將結構化的一手資料研究與產業相關人員的研究結果以及全面的二手證據審查相結合，以確保獲得均衡且檢驗的見解。一手資料研究包括對臨床醫生、採購主管、設備營運經理和監管專家的結構化訪談，從而定性地了解採用障礙、臨床工作流程和醫院決策標準。二手資料包括同行評審的臨床文獻、設備註冊登記、監管備案文件和已發表的臨床試驗結果，為檢驗該技術的性能和安全性提供了實證背景。

為確保分析的嚴謹性，我們透過將相關人員的證詞與已發表的證據和監管文件進行交叉檢驗，以及基於情境的供應鏈和政策變數敏感度檢定來確保分析的嚴謹性。調查方法優先考慮三角檢驗、透明地揭露假設條件，以及與臨床和商業諮詢委員會的磋商，以確保建議切實可行。

總結性結論強調，臨床證據的一致性、營運彈性和適應性商業模式對於確保長期成功至關重要

總而言之，鬱血性心臟衰竭的市場格局由多種因素共同決定：臨床創新、監管審查以及不斷變化的商業模式，這些因素需要靈活的策略和嚴謹的執行。電刺激、機械循環支援和數位監測方面的技術進步不斷拓展治療選擇，而支付方和醫療服務提供者則要求獲得可驗證的療效以及對總護理成本的可預測影響。貿易動態和關稅壓力帶來了額外的營運複雜性，迫使製造商重新考慮其採購和製造佈局，以保持供應的連續性和利潤的完整性。

展望未來，成功的公司將把嚴謹的臨床證據項目與模組化產品架構、彈性供應鏈以及能夠反映本地差異的靈活上市模式相結合。透過協調臨床夥伴關係、報銷參與和數位化服務交付，相關人員可以加速技術應用，改善患者治療效果，並建立能夠抵禦政策和市場波動的永續商業專利權。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將遠端患者監護整合到植入式心臟衰竭設備中可提高依從性
  • 無線通訊起搏系統降低心臟衰竭患者的感染風險
  • 利用血管內能源採集技術開發無電池心臟輔助裝置
  • 投資人工智慧驅動的預測分析平台，實現鬱血性心臟衰竭設備治療的個人化最佳化
  • 針對治療進行性心臟衰竭的自主神經功能障礙的神經調節設備監管核准增加
  • 設備製造商和遠端醫療提供者合作實現心臟再同步治療的虛擬滴定
  • 生物相容性材料的進步可以透過減少排斥反應來延長植入式心臟衰竭支撐裝置的壽命

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章鬱血性心臟衰竭設備市場（依設備類型）

  • 心臟再同步治療裝置
  • 植入式心臟整流去顫器
  • 心室輔助裝置
    • 雙心室輔助裝置
    • 左心室輔助裝置
    • 右心室輔助裝置

第9章鬱血性心臟衰竭設備市場（依治療方法）

  • 電刺激
    • 非同步心律調節器
    • 同步心律調節器
  • 機械循環輔助

第 10 章鬱血性心臟衰竭設備市場（按最終用戶）

  • 門診手術中心
  • 醫院
  • 專科診所

第 11 章鬱血性心臟衰竭設備市場（依通路）

  • 直銷
  • 經銷商
  • 網上銷售

第12章鬱血性心臟衰竭設備市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章鬱血性心臟衰竭設備市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章鬱血性心臟衰竭設備市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic plc
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Abiomed, Inc.
    • Biotronik SE & Co. KG
    • LivaNova PLC
    • Getinge AB
    • MicroPort Scientific Corporation
    • SynCardia Systems LLC
    • Jarvik Heart Inc.
Product Code: MRR-036CEF508588

The Congestive Heart Failure Treatment Device Market is projected to grow by USD 25.64 billion at a CAGR of 8.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.44 billion
Estimated Year [2025] USD 14.60 billion
Forecast Year [2032] USD 25.64 billion
CAGR (%) 8.40%

Concise framing of how clinical, technological, and commercial drivers converge to reshape congestive heart failure device treatment choices and pathways

Congestive heart failure remains one of the most consequential chronic cardiovascular conditions, exerting pressure on clinical systems, care pathways, and device innovators alike. Over the past decade, treatment paradigms have evolved from symptom management toward device-enabled interventions that target electrical coordination and mechanical circulatory support. These shifts reflect advances in implantable technologies, perioperative care, and longitudinal monitoring, and they have created new expectations around device durability, patient quality of life, and downstream care economics.

As clinical teams increasingly integrate remote monitoring and evidence-based selection criteria, manufacturers and providers must align product design with real-world usability and long-term outcomes. Concurrently, regulatory rigor and payer scrutiny demand robust clinical evidence and demonstrable cost-effectiveness. Therefore, stakeholders must balance clinical innovation with pragmatic considerations such as supply chain resilience, distribution models, and end-user training. This introduction frames the subsequent sections by identifying the interconnected clinical, technological, and commercial drivers that dictate near-term strategic choices for device makers, hospital systems, and specialty clinics.

How technological miniaturization, digital connectivity, and value-based care models are driving transformative shifts across device development and clinical adoption landscapes

The landscape for congestive heart failure devices is changing rapidly as innovations in electrical stimulation, mechanical circulatory support, and digital health converge to enable new standards of care. Advances in device miniaturization, battery technology, and software-driven therapy adjustment have expanded the clinical indications and usability of implantable cardioverter defibrillators and cardiac resynchronization therapy devices. Simultaneously, ventricular assist devices are benefitting from improved materials, percutaneous approaches, and enhanced hemodynamic control algorithms that reduce perioperative risk and broaden candidacy for durable support.

In parallel, health systems are adopting value-based procurement and outcomes-linked contracting, which compels manufacturers to prioritize long-term survivorship data, reduced rehospitalization rates, and integrated service models. Digital connectivity has introduced remote patient monitoring as an integral adjunct to device therapy, enabling timely interventions and lowering the burden on acute care settings. Consequently, market participants are shifting from transactional product sales toward comprehensive service portfolios, bundled care offerings, and collaborative care pathways. These transformative shifts demand that clinical, commercial, and regulatory strategies be tightly aligned to maintain competitiveness and to deliver measurable improvements in patient outcomes.

Cumulative qualitative impacts of evolving United States tariff and trade policy dynamics on sourcing, manufacturing localization, and clinical supply continuity

Recent tariff dynamics in the United States have had a cumulative effect on the congestive heart failure device ecosystem, influencing sourcing strategies, manufacturing footprints, and commercial margins. Increased import duties and trade policy uncertainty have prompted many manufacturers to reassess global supply chains, accelerate supplier diversification, and explore regional manufacturing hubs to reduce exposure to cross-border cost volatility. These adjustments have taken place against a backdrop of increased demand for advanced device components such as specialized semiconductors, implantable-grade batteries, and proprietary sensors, all of which are sensitive to geopolitical supply constraints.

As a result, procurement teams and manufacturers have invested in dual-sourcing, qualified secondary suppliers, and enhanced inventory management to mitigate lead-time risk. Meanwhile, service models that rely on consumable components have been recalibrated to account for higher landed costs and potential delays in component availability. Regulatory filings and quality-management systems have also required updates to reflect new sourcing arrangements and to maintain continuity of clinical trials and post-market surveillance. In aggregate, these cumulative impacts have favored organizations that can rapidly adapt sourcing strategies, maintain transparent supplier relationships, and pass through or absorb cost changes while sustaining clinical support and warranty obligations.

How device type, therapeutic modality, end-user settings, and distribution channels interact to shape adoption drivers and commercial strategies in congestive heart failure treatments

Segmentation insights reveal differentiated demand drivers and adoption patterns across device type, therapeutic modality, end users, and distribution channels. When considering device type, cardiac resynchronization therapy devices and implantable cardioverter defibrillators increasingly center on algorithmic synchronization and arrhythmia prevention, while ventricular assist devices require distinct surgical pathways and long-term outpatient support. Within ventricular assist devices, left ventricular assist devices have become the focal point for durable support in advanced left-sided failure, whereas biventricular assist devices and right ventricular assist devices remain crucial for complex hemodynamic cases, often necessitating multi-disciplinary care teams.

Across therapeutic modality, electrical stimulation pathways leverage asynchronous and synchronous pacemaker approaches to restore coordinated contraction and reduce symptomatic burden, while mechanical circulatory support provides direct hemodynamic restoration for patients with advanced or refractory failure. End users exhibit clear differentiation: hospitals manage the full spectrum of acute implantation and complex perioperative care, ambulatory surgical centers facilitate selected device implantations and follow-up for lower-risk procedures, and specialty clinics deliver device management, optimization, and long-term monitoring that drive adherence and early complication detection. Moreover, distribution channel behavior stratifies commercial engagement and adoption cadence; direct sales enable close collaboration with large hospital systems and integrated service contracts, distributors facilitate reach into regional hospital networks and specialty clinics, and online sales platforms create opportunities for standardized consumables, accessories, and remote service subscriptions. Taken together, these segmentation lenses inform targeted product development, tailored clinical training programs, and adaptive go-to-market models that match clinical complexity with appropriate distribution and service investments.

Regional clinical, regulatory, and commercial dynamics that determine adoption patterns and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics continue to shape clinical adoption patterns, regulatory pathways, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and advanced reimbursement structures often favor rapid adoption of evidence-backed device therapies and bundled-care models, while regional differences between public and private payers influence procurement cycles and price negotiations. Moving to Europe, Middle East & Africa, regulatory harmonization efforts coexist with heterogeneous reimbursement environments, prompting manufacturers to deploy region-specific clinical evidence strategies and selective market-entry sequencing to align with national health technology assessment priorities.

In the Asia-Pacific region, the combination of rising prevalence, expanding specialist capacity, and an expanding middle class is accelerating demand; however, manufacturers must tailor device designs and pricing strategies to accommodate varied infrastructure, hospital capabilities, and local regulatory processes. Across all regions, supply chain localization, clinical training partnerships, and investments in remote monitoring infrastructure have emerged as essential components of successful market penetration. By strategically aligning clinical evidence generation, reimbursement modeling, and distribution investments to regional nuances, organizations can maximize adoption while mitigating regulatory and operational risks.

Strategic priorities that distinguish market leaders including evidence generation, platform modularity, and service-oriented commercial models driving competitive advantage

Companies active in congestive heart failure devices are prioritizing clinical evidence generation, platform modularity, and service-oriented commercial models to differentiate in a competitive environment. Leading firms are investing in longitudinal outcome studies and registry integration to demonstrate reductions in rehospitalization and improvements in functional status. Concurrently, product roadmaps emphasize interoperability, software-driven therapy optimization, and upgrades that extend device lifecycles, which enables recurring revenue opportunities through service contracts and remote monitoring subscriptions.

Strategic partnerships with hospitals and specialty clinics are being used to accelerate real-world data collection and to co-develop clinical pathways that ease adoption. In addition, many organizations are pursuing targeted manufacturing investments, including localized production and quality-system enhancements, to reduce exposure to geopolitical risk and tariff fluctuations. Mergers and acquisitions remain an active lever for acquiring niche technologies such as advanced sensors, novel battery chemistry, or AI-enabled diagnostics, while licensing and joint-development agreements allow larger players to expand portfolios without diluting core competencies. Overall, companies that balance disciplined clinical evidence programs with adaptive commercial execution and resilient operational models are best positioned to capture long-term clinical and economic value.

Actionable strategic playbook for device manufacturers and provider partners to secure adoption, manage tariff exposure, and drive durable commercial outcomes

Industry leaders should pursue a set of coordinated actions to preserve clinical credibility, accelerate adoption, and protect margins amidst technological and policy headwinds. First, prioritize generation of robust clinical evidence across diverse patient cohorts and real-world settings to support reimbursement discussions and to demonstrate comparative effectiveness. Second, diversify component sourcing and qualify alternate suppliers while investing in regional manufacturing or assembly capabilities to reduce tariff and logistical exposure. Third, design modular device platforms and software upgrade paths that permit incremental innovation, reduce obsolescence risks, and enable recurring revenue through service offerings.

Additionally, foster deep clinical partnerships with hospitals, specialty clinics, and ambulatory surgical centers to co-create streamlined care pathways and targeted training that reduce implantation complications and optimize follow-up. Integrate remote monitoring and patient-engagement tools to maintain continuity of care and to provide data that supports value-based contracting. Finally, conduct scenario planning for regulatory and tariff shifts, align pricing strategies with payer expectations, and develop clear commercial playbooks for direct sales, distributor partnerships, and digital channels to ensure market coverage and sustainable growth.

Transparent and robust mixed-methods research approach combining stakeholder engagement, clinical evidence review, and supply chain analysis to underpin strategic recommendations

The research methodology underpinning this analysis combined structured primary engagement with industry stakeholders and comprehensive secondary evidence review to ensure balanced, verifiable insights. Primary research included structured interviews with clinicians, procurement leaders, device operations managers, and regulatory experts, enabling qualitative understanding of adoption barriers, clinical workflows, and hospital decision criteria. Secondary inputs comprised peer-reviewed clinical literature, device registries, regulatory filings, and publicly disclosed clinical trial outcomes, which provided empirical context for technology performance and safety considerations.

Analytical rigor was maintained through cross-validation of stakeholder testimony with published evidence and regulatory documentation, and by employing scenario-based sensitivity checks for supply chain and policy variables. Limitations include the inherent lag between ongoing clinical trials and regulatory decisions, and the variability of regional reimbursement frameworks that can affect short-term adoption. To mitigate these constraints, the methodology prioritized triangulation, transparent assumption disclosure, and consultation with clinical and commercial advisory panels to ground recommendations in practical realities.

Concluding synthesis emphasizing the imperative for aligned clinical evidence, resilient operations, and adaptive commercial models to secure long-term success

In conclusion, the congestive heart failure device landscape is defined by converging forces of clinical innovation, regulatory scrutiny, and shifting commercial models that require agile strategy and disciplined execution. Technological advances in electrical stimulation, mechanical circulatory support, and digital monitoring continue to expand therapeutic options, while payers and providers demand demonstrable outcomes and predictable total-cost-of-care impacts. Trade dynamics and tariff pressures have introduced additional operational complexity, compelling manufacturers to rethink sourcing and manufacturing footprints to maintain supply continuity and margin integrity.

Moving forward, successful organizations will integrate rigorous clinical evidence programs with modular product architectures, resilient supply chains, and adaptive go-to-market models that reflect regional nuances. By aligning clinical partnerships, reimbursement engagement, and digital service offerings, stakeholders can accelerate adoption, improve patient outcomes, and build sustainable commercial franchises that withstand policy and market volatility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of remote patient monitoring capabilities in implantable heart failure devices to improve adherence
  • 5.2. Emergence of leadless pacing systems with wireless communication reducing infection risks among heart failure patients
  • 5.3. Development of battery-free cardiac assist devices powered by intravascular energy harvesting techniques
  • 5.4. Investments in AI-driven predictive analytics platforms for personalized optimization of device therapy in congestive heart failure
  • 5.5. Increasing regulatory approvals for neuromodulation devices targeting autonomic imbalance in advanced heart failure treatment
  • 5.6. Collaboration between device manufacturers and telehealth providers to enable virtual titration of cardiac resynchronization therapy
  • 5.7. Advancements in biocompatible materials extending longevity of implantable heart failure support devices through reduced rejection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Congestive Heart Failure Treatment Device Market, by Device Type

  • 8.1. Cardiac Resynchronization Therapy Device
  • 8.2. Implantable Cardioverter Defibrillator
  • 8.3. Ventricular Assist Device
    • 8.3.1. Biventricular Assist Device
    • 8.3.2. Left Ventricular Assist Device
    • 8.3.3. Right Ventricular Assist Device

9. Congestive Heart Failure Treatment Device Market, by Therapeutic Modality

  • 9.1. Electrical Stimulation
    • 9.1.1. Asynchronous Pacemakers
    • 9.1.2. Synchronous Pacemakers
  • 9.2. Mechanical Circulatory Support

10. Congestive Heart Failure Treatment Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Congestive Heart Failure Treatment Device Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. Online Sales

12. Congestive Heart Failure Treatment Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Congestive Heart Failure Treatment Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Congestive Heart Failure Treatment Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Boston Scientific Corporation
    • 15.3.4. Abiomed, Inc.
    • 15.3.5. Biotronik SE & Co. KG
    • 15.3.6. LivaNova PLC
    • 15.3.7. Getinge AB
    • 15.3.8. MicroPort Scientific Corporation
    • 15.3.9. SynCardia Systems LLC
    • 15.3.10. Jarvik Heart Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2024 (USD MILLION)
  • TABLE 248. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2025-2032 (USD MILLION)
  • TABLE 249. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 250. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 251. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION CON